Correlation between the methylation of SULF2 and WRN promoter and the irinotecan chemosensitivity in gastric cancer

BMC Gastroenterology

Baorui Liu²  Jie Shen²  Jun Wang¹  Li Xie²  Lin Wang¹ 

[1] Jiang Su Province Geriatric Institute, Jiang Su Province Geriatric hospital, Nanjing, China;The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University, Clinical Cancer Institute of Nanjing University, Nanjing, China

关键词: Irinotecan;    Methylation;    WRN;    SULF2;    Gastric cancer;   

Others  :  856808
DOI  :  10.1186/1471-230X-13-173

 received in 2012-10-28, accepted in 2013-12-12,  发布年份 2013

【 摘 要 】

Background

At present, no study has compared the correlation between SULF2, WRN promoter methylation and clinicopathological parameters of patients with gastric cancer and the sensitivity to irinotecan (CPT-11).

Methods

We collected 102 fresh tumor tissues from pathologically diagnosed gastric carcinoma patients. Methylation specific PCR was used to detect the promoter methylation of SULF2 and WRN. The chemosensitivity of irinotecan to gastric tomor was tested by MTT. Then we compared the chemosensitivity difference of the methylated group with unmethylated group.

Results

The rates of SULF2, WRN methylation were 28.3% (29/102) and 23.6% (24/102), separately. Patients with SULF2 methylation were more sensitive to CPT-11 than those without SULF2 methylation (P < 0.01). Patients with both SULF2 and WRN methylation were also more sensitive to CPT-11 than others ( P < 0.05).

Conclusion

SULF2 and WRN promoter methylation detection indicates potential predictive biomarkers to identify and target the most sensitive gastric cancer subpopulation for personalized CPT-11 therapy.

【 授权许可】

   
2013 Wang et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Jemal A, Bray F, Center MM, et al.: Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
• [2]Fadi SF: A general review of the role of irinotecan (CPT11) in the treatment of gastric cancer. Med Oncol 2007, 24:137-146.
• [3]Tessema M, Yingling CM, Thomaa CL, et al.: SULF2 methylation is prognostic for lung cancer survival and increases sensitivity to topoisomerase-I inhibitors via induction of ISG15. Oncogene 2011, 12:1-10.
• [4]Agrelo R, Cheng WH, Fernando S, et al.: Epigenetic inactivation of the premature aging Werner syndrome gene in human cancer. Proc Natl Acad Sci U S A 2006, 103:8823-8827.
• [5]Yoshimasu T, Oura S, Hirai I, et al.: Data acquisition for the histoculture drug response assay in lung cancer. J Thorac Cardiovasc Surg 2007, 133:303-308.
• [6]TETSURO K: Chemotherapy strategies for gastric cancer. In Vivo 2008, 22:273-278.
• [7]Das PM, Singal R: DNA methylation and cancer. J Clin Oncol 2004, 22:4632-4642.
• [8]Rashid A, Issa JP: CpG island methylation in gastroenterologic neoplasia: a maturing field. Gastroenterology 2004, 127:1578-1588.
• [9]Uchimura K, Morimoto-Tomita M, Bistrup A, et al.: Sulf-2, an extracellular endoglucosamine-6-sulfatase, selectively mobilizes heparin-bound growth factors and chemokines: effects on VEGF, FGF-1, and SDF-1. BMC Biochem 2006, 7:2-14. BioMed Central Full Text
• [10]Lai JP, Sandhu DS, Yu C, Han T, Moser CD, Jackson KK, et al.: Sulfatase 2 up-regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma. Hepatology 2008, 47:1211-1222.
• [11]Morimoto-Tomita M, Uchimura K, Bistrup A, Lum DH, Egeblad M, Boudreau N, et al.: Sulf-2, a proangiogenic heparin sulfate endosulfatase, is upregulated in breast cancer. Neoplasia 2005, 7:1001-1010.
• [12]Lemjabbar-Alaoui H, van Zante A, Singer MS, Xue Q, Wang YQ, Tsay D, et al.: Sulf-2, a heparan sulfate endosulfatase, promotes human lung carcinogenesis. Oncogene 2010, 29:635-646.
• [13]Desai SD, Wood LM, Tsai YC, et al.: ISG15 as a novel tumor biomarker for drug sensitivity. Mol Cancer Ther 2008, 7:1430-1439.
• [14]Tessema M, Yu YY, Stidley CA, Machida EO, Schuebel KE, Baylin SB, et al.: Concomitant promoter methylation of multiple genes in lung adenocarcinomas from current, former and never smokers. Carcinogenesis 2009, 30:1132-1138.
• [15]Agrelo R, Cheng WH, Setien F, et al.: Epigenetic inactivation of the premature aging Werner syn-drome gene in human cancer. Proc Natl Acad Sci U S A 2006, 103:8822-8827.
• [16]Wen-Hsing C, Rika K, Patricia L, Opresko : Collaboration of Werner syndrome protein and BRCA1 in cellular responses to DNA interstrand cross-links. Nucleic Acids Res 2006, 34:92751-92760.
• [17]Monika A, Joshua A, Sommers , Robert H: Hoemaker, inhibition of helicase activity by a small molecule impairs Werner syndrome helicase (WRN) function in the cellular response to DNA damage or replication stress. Proc Natl Acad Sci U S A 2011, 108(40):1525-1530.
• [18]Furukawa T, Kubota T, Hoffman RM: Clinical applications of the histoculture drug response assay. Clin Cancer Res 1995, 1:305-311.
• [19]Hayashi Y, Kuriyama H, Umezu H, Tanaka J, Yoshimasu T, Furukawa T: Class III beta-tubulin expression in tumor cells is correlated with resistance to docetaxel in patients with completely resected non-small-cell lung cancer. InternMed 2009, 48:203-208.
• [20]Koopman M, Knijn N, Richman S, et al.: The correlation between topoisomerase-I (Topo1) expression and outcome of treatment with capecitabine and irinotecan in advanced colorectal cancer (ACC) patients (pts) treated in the CAIRO study of the Dutch Colorectal Cancer Group (DCCG). Eur J Cancer 2009, 7:321-325.
• [21]Hoskins JM, Marcuello E, Altes A, et al.: Irinotecan pharmacogenetics: influence of pharmacodynamic genes. Clin Cancer Re 2008, 14:1788-1796.
• [22]Higinio D, Silvia ML, Elena E, et al.: Aprataxin tumor levels predict response of colorectal cancer patients to irinotecan-based treatment. Clin Cancer Res 2010, 16(8):2375-2382.